Odyssey Therapeutics, Inc.

Healthcare

NASDAQ:ODTX · NASDAQ Global Market

Market Cap $550.99M Beta 0.00
$19.07 -0.05%

-$0.01 today

52W Low $15.35High $20.30

Vol 1.15M · Avg 0.43M

Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

No return metrics data available.

Management

Key executives, compensation & ownership

Management
NameTitleCompensationTenureAgeShares OwnedOwnership %

Jason Haas

Chief Financial Officer$702,500.0058

Gary D. Glick

Founder, President, CEO & Director$558,900.0064

Collin Todd

Senior Vice President of Strategy & Business Development$544,900.0034

Eicke Latz

Scientific Co-Founder

Joseph McDonald

Chief Data Officer

Natalie Dales

Chief of Research Operations & Portfolio Strategy56

Jolie Siegel

Executive VP, General Counsel & Secretary49

Felix Meissner

Scientific Co-Founder

Florian.I Schmidt

Scientific Co-Founder

Kim Lewis

Scientific Co-Founder

Insider Trading

SEC Form 4 transactions — last 12 months

Management

No insider transactions in the last 12 months.

Growth Analysis

Historical CAGR & forward analyst estimates

No growth data available

Competitors

Peer companies in the same sector

Health

No competitor data available.

Who manages ODTX?

Odyssey Therapeutics, Inc. (ODTX) lists 10 active executives. The top listed executive is Eicke Latz, Scientific Co-Founder.

Explore More

Continue the stock analysis

Jump to another research area for this company.